Serum-based measurements of stromal activation through ADAM12 associate with poor prognosis in colorectal cancer

Serum-based measurements of stromal activation through ADAM12 associate with poor prognosis in colorectal cancer

Background: Recently it has been recognized that stromal markers could be used as a clinically relevant biomarker for therapy response and prognosis. Here, we report on a serum marker for stromal activation, A Disintegrin and Metalloprotease 12 (ADAM12) in colorectal cancer (CRC). Methods: Using gen...

Full description

Bibliographic Details
Main Authors: Bijlsma, M.F (Author), Bootsma, S. (Author), Damhofer, H. (Author), Goey, K.K.H (Author), Koopman, M. (Author), Medema, J.P (Author), Mesker, W.E (Author), Mol, L. (Author), Punt, C.J.A (Author), Smits, L.J.H (Author), ten Hoorn, S. (Author), Trinh, A. (Author), Tuynman, J.B (Author), van Oijen, M.G.H (Author), van Pelt, G.W (Author), Vermeulen, L. (Author), Waasdorp, C. (Author), Zhao, L. (Author), Zlobec, I. (Author)
Format: Article
Language:English
Published: BioMed Central Ltd 2022
Subjects:
ADAM12
Colorectal cancer
Prognostic marker
Stroma
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items